The diagnostic and prognostic role of cerebrospinal fluid biomarkers in glucose transporter 1 deficiency: a systematic review
-
Published:2024-07-02
Issue:9
Volume:183
Page:3665-3678
-
ISSN:1432-1076
-
Container-title:European Journal of Pediatrics
-
language:en
-
Short-container-title:Eur J Pediatr
Author:
Mastrangelo Mario,Manti Filippo,Ricciardi Giacomina,Cinnante Elisa Maria Colacino,Cameli Noemi,Beatrice Annachiara,Tolve Manuela,Pisani Francesco
Abstract
AbstractThe purpose of this study is to investigate the diagnostic and prognostic role of cerebrospinal fluid (CSF) biomarkers in the diagnostic work-up of glucose transporter 1 (GLUT1) deficiency. Reported here is a systematic review according to PRISMA guidelines collecting clinical and biochemical data about all published patients who underwent CSF analysis. Clinical phenotypes were compared between groups defined by the levels of CSF glucose (≤ 2.2 mmol/L versus > 2.2 mmol/L), CSF/blood glucose ratio (≤ 0.45 versus > 0.45), and CSF lactate (≤ 1 mmol/L versus > 1 mmol/L). Five hundred sixty-two patients fulfilled the inclusion criteria with a mean age at the diagnosis of 8.6 ± 6.7 years. Patients with CSF glucose ≤ 2.2 mmol/L and CSF/blood glucose ratio ≤ 0.45 presented with an earlier onset of symptoms (16.4 ± 22.0 versus 54.4 ± 45.9 months, p < 0.01; 15.7 ± 23.8 versus 40.9 ± 38.0 months, p < 0.01) and received an earlier molecular genetic confirmation (92.1 ± 72.8 versus 157.1 ± 106.2 months, p < 0.01). CSF glucose ≤ 2.2 mmol/L was consistently associated with response to ketogenic diet (p = 0.018) and antiseizure medications (p = 0.025). CSF/blood glucose ratio ≤ 0.45 was significantly associated with absence seizures (p = 0.048), paroxysmal exercise‐induced dyskinesia (p = 0.046), and intellectual disability (p = 0.016) while CSF lactate > 1 mmol/L was associated with a response to antiseizure medications (p = 0.026) but not to ketogenic diet.Conclusions:This systematic review supported the diagnostic usefulness of lumbar puncture for the early identification of patients with GLUT1 deficiency responsive to treatments especially if they present with co-occurring epilepsy, movement, and neurodevelopmental disorders.
What is Known:
• Phenotypes of GLUT1 deficiency syndrome range between early epileptic and developmental encephalopathy to paroxysmal movement disorders and developmental impairment
What is New:
• CSF blood/glucose ratio may predict better than CSF glucose the diagnosis in children presenting with early onset absences
• CSF blood/glucose ratio may predict better than CSF glucose the diagnosis in children presenting with paroxysmal exercise induced dyskinesia and intellectual disability.
• CSF glucose may predict better than CSF blood/glucose and lactate the response to ketogenic diet and antiseizure medications.
Publisher
Springer Science and Business Media LLC
Reference152 articles.
1. Koch H, Weber YG (2019) The glucose transporter type 1 (GLUT1) syndromes. Epilepsy Behav 91:90–93 2. Klepper J, Leiendecker B (2007) GLUT1 deficiency syndrome–2007 update. Dev Med Child Neurol 49:707–16 3. Schwantje M, Verhagen LM, Hasselt PM, Fuchs SA (2020) Glucose transporter type 1 deficiency syndrome and the ketogenic diet. J Inherit Metab Dis 43:216–222 4. Mochel F, Gras D, Luton MP, Nizou M, Giovannini D, Delattre C, Aubart M, Barth M, De Saint-Martin A, Doummar D, Essid N, Garros A, Le Camus CH, Hoebeke C, The Tich SN, Perivier M, Rivera S, Rolland A, Roubertie A, Sarret C, Sevin C, Ville D, Sitbon M, Costa JM, Pons R, Garcia-Cazorla A, Vuillaumier S, Petit V, Boespflug-Tanguy O, De Vivo DC; MetaGLUT1 Study Group. Prospective multicenter validation of a simple blood test for the diagnosis of GLUT1 deficiency syndrome. Neurology. 2023; 100(23): e2360-e2373. 5. Peters TMA, Merx J, Kooijman PC, Noga M, de Boer S, van Gemert LA, Salden G, Engelke UFH, Lefeber DJ, van Outersterp RE, Berden G, Boltje TJ, Artuch R, Pías-Peleteiro L, García-Cazorla Á, Barić I, Thöny B, Oomens J, Martens J, Wevers RA, Verbeek MM, Coene KLM, Willemsen MAAP (2023) Novel cerebrospinal fluid biomarkers of glucose transporter type 1 deficiency syndrome: implications beyond the brain’s energy deficit. J Inherit Metab Dis. 46(1):66–75
|
|